Comparative Pharmacology
Head-to-head clinical analysis: POMALIDOMIDE versus THALIDOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POMALIDOMIDE versus THALIDOMIDE.
POMALIDOMIDE vs THALIDOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.
Immunomodulatory and antiangiogenic action: TNF-alpha inhibitor, alters adhesion molecule expression, inhibits angiogenesis via VEGF/FGF inhibition, modulates T-cell co-stimulation and NF-κB activity.
4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.
100 mg orally once daily, preferably at bedtime to minimize sedation; maximum dose 400 mg daily for multiple myeloma or erythema nodosum leprosum.
MODERATE Risk
MODERATE Risk
Clinical Note
moderateThalidomide + Digoxin
"Thalidomide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePomalidomide + Digoxin
"Pomalidomide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateThalidomide + Digitoxin
"Thalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePomalidomide + Digitoxin
"Pomalidomide may decrease the cardiotoxic activities of Digitoxin."
Terminal half-life approximately 7.5 hours in patients with normal renal function; prolonged to 9-12 hours in moderate renal impairment.
Terminal elimination half-life is approximately 5-7 hours in healthy adults, but may be prolonged to 7-10 hours in patients with renal impairment or advanced age.
Renal (73% as unchanged drug and metabolites), fecal (15%), biliary (minimal).
Thalidomide is primarily eliminated by nonenzymatic hydrolysis in plasma and tissues; renal excretion accounts for <1% of unchanged drug; metabolites are excreted renally (~90%) and fecally (~10%).
Category C
Category D/X
Immunomodulatory Agent
Immunomodulatory Agent